Study identifier:4054IL/0004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
-
Prostatic Neoplasms
Phase 2
No
ZD4054 10 mg, ZD4054 15 mg, ZD4054 22.5 mg
Male
22
Interventional
18 Years +
Allocation: None
Endpoint Classification: None
Intervention Model: None
Masking: None
Primary Purpose: Treatment
Verified 01 Oct 2012 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: ZD4054 10 mg 1 x 10 mg oral tablets once daily | Drug: ZD4054 10 mg 1 x 10 mg oral tablets once daily Other Name: Zibotentan, |
Experimental: ZD4054 15 mg 1 x 10 mg + 2 x 2.5 mg oral tablets once daily | Drug: ZD4054 15 mg 1 x 10 mg + 2 x 2.5 mg oral tablets once daily Other Name: Zibotentan |
Experimental: ZD4054 22.5 mg 2 x 10 mg + 1 x 2.5 mg oral tablets once daily | Drug: ZD4054 22.5 mg 2 x 10 mg + 2 x 2.5 mg oral tablets once daily Other Name: Zibotentan |